原发性高血压患者血清PIP水平的变化及其与ET-1相关性的研究

The Changes of Serum PIP in Patients with Essential Hypertension and its Relationship with the Level of ET-1

目的分析原发性高血压病患者血清胶原代谢的标志物I型前胶原羧基端肽(PIP)水平的变化,并探讨其与血浆内皮素(ET-1)水平之间的关系。方法研究对象包括50例高血压病患者和44例健康对照者。采用双抗体夹心ABC-ELISA法测定血清PIP浓度,放射免疫分析法(RIA)测定血浆ET-1浓度。采用彩色超声心动图诊断仪进行检查,将高血压病患者分为心肌肥厚组(LVH)和非心肌肥厚组(NLVH)。结果显示LVH、NLVH两组PIP、ET-1水平与正常对照组相比均显著升高(P<0.01),而且LVH组PIP、ET-1水平明显高于NLVH组(P<0.05)。直线相关分析发现,高血压病患者的血清PIP浓度与ET-1水平呈明显正相关(r=0.440,P<0.01)。结论高血压病患者体内胶原合成增加,左室肥厚患者更加明显,高血压病患者发生不同程度心肌纤维化,而且左室肥厚患者心肌纤维化程度更加严重,内皮素在心肌纤维化中可能具有一定作用。

Objective To study the changes of serum procollagen type Ⅰ C-terminal peptide （PIP） in patients with essential hypertension and its relationship with the level of endothelin-1 （ET-1） in plasma. Methods Fifty hypertensives and forty-four healthy subjects were included in the study. The serum concentrations of PIP were measured by ABC-ELISA method. The plasma concentrations of ET-1 were measured by specific radioimmunoassay. The hypertensive patients were divided into LVH group and NLVH group by the results echocardiographic study. Results The serum concentrations of PIP in control group, LVH group and NLVH group were 72.13±30.17 ng/ml, 134.93±67.71 ng/ml,94.43±56.92 ng/ml respectively. The plasma concentrations of ET-1 in three groups were 54.26±17.18 pg/ml,92.32±30.31 pg/ ml,69.62±21.24 pg/ml respectively. The levels of PIP and ET-1 were significantly higher in both hypertensive groups than that in control group（P 〈 0.01 ）,and the levels of the two parameters in LVH group were obviously higher than that in NLVH group（P 〈 0.05）. there was a very close correlation between the serum concentrations of PIP and the plasma concentrations of ET-1 in essential hypertensive patients （r = 0.440, P 〈 0.01 ）.Conclusion The serum concentrations of PIP elevated in patients with essential hypertension, which indicated the amount of collagen biosynthesis increased and reflected ongoing myocardial fibrosis. The degree of MF was more serious in LVH group. ET-1 may play an important role during the development of MF.